Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003715 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Phase 2 study, sponsored by AVAX Technologies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 425
- Enrollment target
NCT00003715 is a Phase 2 study that was terminated before completion, run by AVAX Technologies. The registered enrollment target is 425 participants.
The verdict
NCT00003715, a Phase 2 study, was terminated before completion, sponsored by AVAX Technologies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 425 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Interventions
- DRUG cyclophosphamide
- DRUG chemotherapy
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL BCG vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 1998-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003715
The ClinicalTrials.gov registry entry for NCT00003715 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 425 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVAX Technologies, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003715 about?
NCT00003715 is a clinical study titled "Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma". RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alf...
What is the current status of trial NCT00003715?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 425 participants. The study started on 1998-12.
What interventions are being tested in trial NCT00003715?
The interventions under investigation include: cyclophosphamide (DRUG), chemotherapy (DRUG), recombinant interferon alfa (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), BCG vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003715?
This trial is sponsored by AVAX Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.